WeVote
Log In

Bill

Bill

SB 166

An Act establishing the Alaska mental health and psychedelic medicine task force; and providing for an effective date.

33rd Legislature (2023-2024) Introduced by Forrest Dunbar and 2 co-sponsors

Alaska establishes mental health task force to study psychedelic medicine research and recommend treatment policy options to legislators.

(S) COSPONSOR(S): TOBIN
#appointments #boards&commissions #business #drugs #legislature #medicalcare #mentalhealth #physicians
0
WeVote Research Nonpartisan
Bill Summary · SB 166

Legislative bill overview

SB 166 establishes a task force in Alaska to study mental health treatment approaches and psychedelic medicines, including their potential therapeutic applications. The task force would be responsible for reviewing current research, examining regulatory frameworks, and making recommendations to the state legislature on policy options.

Why is this important

Mental health conditions affect significant portions of Alaska's population, and psychedelic-assisted therapies have shown promising clinical results in recent research for conditions like PTSD, depression, and end-of-life anxiety. This task force represents a state-level examination of emerging treatments that could eventually expand treatment options for Alaskans, though such therapies remain federally controlled substances with limited legal therapeutic frameworks outside clinical trials.

Potential points of contention

  • Federal-state legal conflict: Psychedelics like psilocybin and MDMA remain Schedule I/II controlled substances federally, creating tension between state exploration and federal drug policy
  • Clinical evidence standards: Debate over whether current research sufficiently supports therapeutic claims, or whether more rigorous long-term studies are needed before policy recommendations
  • Implementation costs and scope: Questions about task force budget (notably marked "ZERO" fiscal note), membership composition, timeline, and whether recommendations could lead to costly regulatory changes or clinical infrastructure investments

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.